Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma

Next Previous
Trial Profile

A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Neovascular glaucoma
  • Focus Registrational; Therapeutic Use
  • Acronyms VEGA
  • Sponsors Bayer

Most Recent Events

  • 16 Dec 2020 Primary endpoint (Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1) has not been met, as per results published in the Advances in Therapy
  • 16 Dec 2020 Results published in the Advances in Therapy
  • 27 Mar 2020 According to a Bayer media release, the company announced that Bayer Yakuhin has received approval for the additional indication of neovascular glaucoma for the intravitreal VEGF inhibitor EYLEAsolution for intravitreal injection 40 mg/mL. This approval is based on the data from two Phase III studies (VEGA and VENERA).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top